Key Takeaways from the GAIN Trial
Keystone Bio acknowledges Cortexyme's efforts in advancing Alzheimer’s disease research through its recently published Ph ll/lll GAIN Trial preliminary results.
Although the trial did not meet its endpoints, it demonstrated that reduction of Pg infection in the oral cavity results in slowing the progression of Alzheimer’s disease in individuals who are Pg positive (Pg+) in the mouth.
From Keystone Bio CEO
“From Keystone Bio’s perspective, the GAIN trial results are a positive advancement relating Pg's oral source and its removal to the prevention and ultimately the elimination of chronic inflammatory diseases.”
- Dr. Daniel Sindelair, DMD, Keystone Bio’s chief executive officer.